Journal of Diagnostics Concepts & Practice >
The application value of determination of hemostasis and thrombosis in tumor patients
Received date: 2023-06-27
Online published: 2023-12-18
Abnormal coagulation function is an important feature of the occurrence and development of malignant tumors. Tumor cells release pro-angiogenic factors that cause vascular endothelial damage and induce platelet activation and proliferation, all of which increase the risk of thrombosis. Cancer patients often present with shortened APTT and PT, elevated fibrinogen, D-dimer and platelet counts, and a hypercoagulable state. With thrombosis forms, the fibrinolytic system is activated, and D-dimer and fibrin degradation product (FDP) increase. Both are commonly used markers of the fibrinolytic system. FDP/D-dimer ratio may improve the accuracy of diagnosing thrombosis or bleeding. New coagulation markers, such as platelet function and platelet surface markers, can be used to assess platelet activation. During the hypercoagulable state and the fibrinolysis process of tumors, four new thrombosis factors are discovered: thrombin-antithrombin (TAT), plasmin α2-plasmin inhibitor complex (PIC), tissue plasminogen activator-inhibitor 1 complex (t-PAIC) and thrombomodulin, which can be used as diagnostic markers for malignant tumors and thrombosis. Thromboelastography simultaneously reflects coagulation factor activity, fibrinogen activity, platelet counts and function, and demonstrates the overall dynamic process of coagulation and fibrinolysis. The 6 traditional coagulation tests combined with platelet count, the 4 new thrombosis tests combined with D-dimer and FDP tests, as well as various thrombosis risk assessment models, play an important role in the prognosis assessment of different tumors. With the development of artificial intelligence and new indicators, the application prospects of coagulation abnormality detection will be broader.
WANG Yanchun, LU Renquan . The application value of determination of hemostasis and thrombosis in tumor patients[J]. Journal of Diagnostics Concepts & Practice, 2023 , 22(04) : 341 -347 . DOI: 10.16150/j.1671-2870.2023.04.003
| [1] | MAHAJAN A, BRUNSON A, WHITE R, et al. The epidemiology of cancer-associated venous thromboembolism: an update[J]. Semin Thromb Hemost, 2019, 45(4):321-325. |
| [2] | ADMASU F T, DEJENIE T A, AYEHU G W, et al. Evaluation of thromboembolic event, basic coagulation parameters, and associated factors in patients with colorectal cancer: a multicenter study[J]. Front Oncol, 2023, 13:1143122. |
| [3] | FALANGA A, RUSSO L, MILESI V, et al. Mechanisms and risk factors of thrombosis in cancer[J]. Crit Rev Oncol Hematol, 2017, 118:79-83. |
| [4] | FALANGA A, MARCHETTI M, VIGNOLI A. Coagulation and cancer: biological and clinical aspects[J]. J Thromb Haemost, 2013, 11(2):223-233. |
| [5] | MAHAJAN A, WUN T. Biomarkers of cancer-associated thromboembolism[J]. Cancer Treat Res, 2019, 179:69-85. |
| [6] | 郝庆刚, 孙凤桂, 严程浩, 等. MT1-MMP在肿瘤转移中的研究进展[J]. 遗传, 2022, 44(9): 745-755. |
| [6] | HAO Q G, SUN F G, YAN C H, et al. Progress on the role and mechanism of MT1-MMP in tumor metastasis[J]. Yi Chuan, 2022, 44(9):745-755. |
| [7] | 陈罗军, 田景媛, 李娜, 等. 血小板在促进肿瘤进展中的作用[J]. 国际肿瘤学杂志, 2018, 45(2):103-106. |
| [7] | CHEN L J, TIAN J Y, LI N, et al. Roles of platelets in tumor progression[J]. J Int Oncol, 2018, 45(2):103-106 |
| [8] | HUFNAGEL D H, COZZI G D, CRISPENS M A, et al. Platelets, thrombocytosis, and ovarian cancer prognosis: surveying the landscape of the literature[J]. Int J Mol Sci, 2020, 21(21):8169. |
| [9] | KVOLIK S, JUKIC M, MATIJEVIC M, et al. An overview of coagulation disorders in cancer patients[J]. Surg Oncol, 2010, 19(1):e33-46. |
| [10] | DAVIS E J, SALEM J E, YOUNG A, et al. Hematologic complications of immune checkpoint inhibitors[J]. Oncologist, 2019, 24(5):584-588. |
| [11] | MEI H, CHEN F, HAN Y, et al. Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy[J]. Chin Med J (Engl), 2022, 135(14):1639-1641. |
| [12] | ELYAMANY G, ALZAHRANI A M, BUKHARY E. Cancer-associated thrombosis: an overview[J]. Clin Med Insights Oncol, 2014, 8:129-137. |
| [13] | KHORANA A A, MACKMAN N, FALANGA A, et al. Cancer-associated venous thromboembolism[J]. Nat Rev Dis Primers, 2022, 8(1):11. |
| [14] | 马昀菲. 全麻复合腰方肌阻滞对腹腔镜胃癌根治术患者围术期凝血功能的影响[D]. 山东: 山东大学, 2022. |
| [14] | MA Y F. The effect of general anesthesia combined with lumbar quadratus muscle block on perioperative coagulation function in patients undergoing laparoscopic radical gastrectomy for gastric cancer[D]. Shandong: Shandong University, 2022. |
| [15] | Bayleyegn B, Adane T, Getawa S, et al. Coagulation parameters in lung cancer patients: a systematic review and meta-analysis[J]. J Clin Lab Anal, 2022, 36(7):e24550. |
| [16] | NASSER N J, FOX J, AGBARYA A. Potential mechanisms of cancer-related hypercoagulability[J]. Cancers (Basel), 2020, 12(3):566. |
| [17] | CAUCHIE P, CAUCHIE C, BOUDJELTIA K Z, et al. Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital -- meaning of the ISTH score system, fibrin monomers, and lipoprotein-C-reactive protein complex formation[J]. Am J Hematol, 2006, 81(6):414-419. |
| [18] | MAHMOOD N, RABBANI S A. Fibrinolytic system and cancer: diagnostic and therapeutic applications[J]. Int J Mol Sci, 2021, 22(9):4358. |
| [19] | Ay C, Dunkler D, Pirker R, et al. High D-dimer levels are associated with poor prognosis in cancer patients[J]. Haematologica, 2012, 97(8):1158-1164. |
| [20] | LYMAN G H, KHORANA A A, FALANGA A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer[J]. J Clin Oncol, 2007, 25(34):5490-5505. |
| [21] | MANDERSTEDT E, LIND-HALLDéN C, HALLDéN C, et al. Genetic variation of the blood coagulation regulator tissue factor pathway inhibitor and venous thromboembolism among middle-aged and older adults: a population-based cohort study[J]. Res Pract Thromb Haemost, 2022, 6(7):e12842. |
| [22] | CHEN Y, WANG Y, XIE S, et al. A risk of venous thromboembolism algorithm as a predictor of venous thromboembolism in patients with colorectal cancer[J]. Clin Appl Thromb Hemost, 2021, 27:10760296211064900. |
| [23] | 谭树芬, 杨琳琳, 何利平, 等. 紫杉醇联合卡铂化疗对卵巢癌凝血/纤溶及CA125/HE4水平的调控及临床意义[J]. 中国病理生理杂志, 2023, 39(3):503-509. |
| [23] | TAN S F, YANG L L, YANG L P, et al. Regulation and clinical significance of paclitaxel with carboplatin com-bined chemotherapy on coagulation/fibrinolysis and CA125/HE4 levels in ovarian cancer[J]. Chin J Pathophysiol, 2023, 39(3):503-509. |
| [24] | BLONSKI W, SIROPAIDES T, REDDY K R. Coagulopathy in liver disease[J]. Curr Treat Options Gastroenterol, 2007, 10(6):464-473. |
| [25] | FANG P, DU L, CAI D. Evaluation of plasma D-dimer for the diagnosis in Chinese patients with hepatocellular carcinoma: a meta-analysis[J]. Medicine (Baltimore), 2020, 99(12):e19461. |
| [26] | FENG H, LI B, LI Z, et al. PIVKA-Ⅱ serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma[J]. BMC cancer, 2021, 21(1):401. |
| [27] | HERMSEN J, HAMBLEY B. The coagulopathy of acute promyelocytic leukemia: an updated review of pathophysiology, risk stratification, and clinical management[J]. Cancers (Basel), 2023, 15(13):3477. |
| [28] | KANAJI N, MIZOGUCHI H, INOUE T, et al. Clinical features of patients with lung cancer accompanied by thromboembolism or disseminated intravascular coagulation[J]. Ther Clin Risk Manag, 2018, 14:1361-1368. |
| [29] | HAO Z, LV H, TAN R, et al. A three-dimensional microfluidic device for monitoring cancer and chemotherapy-associated platelet activation[J]. ACS Omega, 2021, 6(4):3164-3172. |
| [30] | ZHOU K, ZHANG J, ZHENG Z R, et al. Diagnostic and prognostic value of TAT, PIC, TM, and t-PAIC in malignant tumor patients with venous thrombosis[J]. Clin Appl Thromb Hemost, 2020, 26:1076029620971041. |
| [31] | KHORANA A A, MACKMAN N, FALANGA A, et al. Cancer-associated venous thromboembolism[J]. Nat Rev Dis Primers, 2022, 8(1):11. |
| [32] | BUCEK R A, REITER M, QUEHENBERGER P, et al. Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor Ⅶ in suspected deep vein thrombosis: is there a place for new parameters?[J]. Br J Haematol, 2003, 120(1):123-128. |
| [33] | ZHOU Y, GUO Y, CUI Q, et al. Application of thromboelastography to predict lung cancer stage[J]. Technol Cancer Res Treat, 2020, 19:1533033820952351. |
| [34] | KHORANA A A, KUDERER N M, MCCRAE K, et al. Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels[J]. Cancer Med, 2020, 9(21):8062-8073. |
| [35] | MEHTA Y, BHAVE A. A review of venous thromboembolism risk assessment models for different patient populations: What we know and don't![J]. Medicine (Baltimore), 2023, 102(2):e32398. |
| [36] | CHEN Y, WANG Y, XIE S, et al. A risk of venous thromboembolism algorithm as a predictor of venous thromboembolism in patients with colorectal cancer[J]. Clin Appl Thromb Hemost, 2021, 27:10760296211064900. |
| [37] | MEI H, JIANG Y, LUO L, et al. Evaluation the combined diagnostic value of TAT, PIC, tPAIC, and sTM in disseminated intravascular coagulation: A multi-center prospective observational study[J]. Thromb Res, 2019, 173:20-26. |
| [38] | 周坤, 周玉珍, 郑遵荣, 等. 血栓四项在恶性肿瘤患者静脉血栓形成中的应用研究[J]. 中国医师进修杂志, 2019, 42(11):994-999. |
| [38] | ZHOU K, ZHOU Y Z, ZHENG Z R, et al. Application of four items of thrombosis detection in venous thrombosis of malignant tumor patients[J]. Chin J Postgrad Med, 2019, 42(11):994-999 |
| [39] | GáLVEZ J A, PAPPAS J M, AHUMADA L, et al. The use of natural language processing on pediatric diagnostic radiology reports in the electronic health record to identify deep venous thrombosis in children[J]. J Thromb Thrombolysis, 2017, 44(3):281-290. |
| [40] | FEI Y, HU J, GAO K, et al. Predicting risk for portal vein thrombosis in acute pancreatitis patients: A comparison of radical basis function artificial neural network and logistic regression models[J]. J Crit Care, 2017, 39:115-123. |
| [41] | ROCHEFORT C M, VERMA A D, EGUALE T, et al. A novel method of adverse event detection can accurately identify venous thromboembolisms (VTEs) from narrative electronic health record data[J]. J Am Med Inform Assoc, 2015, 22(1):155-165. |
| [42] | LIU K, CHEN J, ZHANG K, et al. A diagnostic prediction model of acute symptomatic portal vein thrombosis[J]. Ann Vasc Surg, 2019, 61:394-399. |
| [43] | WANG Q, YUAN L, DING X, et al. Prediction and diagnosis of venous thromboembolism using artificial intelligence approaches: a systematic review and meta-analysis[J]. Clin Appl Thromb Hemost, 2021, 27:10760296211021162. |
/
| 〈 |
|
〉 |
